{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T23:36:33Z","timestamp":1720913793165},"reference-count":43,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"vor","delay-in-days":366,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","valueinhealthjournal.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.jval.2015.08.007","type":"journal-article","created":{"date-parts":[[2015,10,21]],"date-time":"2015-10-21T02:06:43Z","timestamp":1445393203000},"page":"1079-1087","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial"],"prefix":"10.1016","volume":"18","author":[{"given":"Vasily","family":"Belozeroff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn M.","family":"Chertow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher N.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bastian","family":"Dehmel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick S.","family":"Parfrey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew H.","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2015.08.007_bib1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/sj.ki.5002287","article-title":"Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics","volume":"74","author":"Goodman","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.jval.2015.08.007_bib2","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/sj.ki.5001754","article-title":"Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study","volume":"70","author":"Jadoul","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.jval.2015.08.007_bib3","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/ndt\/gfq219","article-title":"Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population","volume":"26","author":"Floege","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jval.2015.08.007_bib4","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jval.2015.08.007_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2369-14-88","article-title":"Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis","volume":"14","author":"Natoli","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jval.2015.08.007_bib6","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1185\/030079907X199790","article-title":"Economic burden of cardiovascular events and fractures among patients with end-stage renal disease","volume":"23","author":"Doan","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jval.2015.08.007_bib7","first-page":"e24","article-title":"Costs of treatment and clinical events for secondary hyperparathyroidism","volume":"5","author":"Lee","year":"2013","journal-title":"Am J Pharm Ben"},{"key":"10.1016\/j.jval.2015.08.007_bib8","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1471-2369-13-140","article-title":"Impact of mineral and bone disorder on healthcare resource use and associated costs in the European Fresenius medical care dialysis population: a retrospective cohort study","volume":"13","author":"Chiroli","year":"2012","journal-title":"BMC Nephrol"},{"issue":"Suppl.","key":"10.1016\/j.jval.2015.08.007_bib9","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","volume":"76","author":"Moe","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.jval.2015.08.007_bib10","unstructured":"Amgen-USPI (2013). Cinacalcet PI US 2013."},{"key":"10.1016\/j.jval.2015.08.007_bib11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3111\/13696998.2012.664799","article-title":"Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States","volume":"15","author":"Boer","year":"2012","journal-title":"J Med Econ"},{"key":"10.1016\/j.jval.2015.08.007_bib12","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1524-4733.2008.00329.x","article-title":"Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA","volume":"11","author":"Ray","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2015.08.007_bib13","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2165\/11538600-000000000-00000","article-title":"Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy","volume":"28","author":"Eandi","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2015.08.007_bib14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2165\/11597980-000000000-00000","article-title":"A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries","volume":"10","author":"Iannazzo","year":"2012","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.jval.2015.08.007_bib15","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/ndt\/gfl774","article-title":"The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective","volume":"22","author":"Garside","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jval.2015.08.007_bib16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1053\/j.ajkd.2011.12.034","article-title":"Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan","volume":"60","author":"Komaba","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jval.2015.08.007_bib17","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2015.08.007_bib18","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"on behalf of the SHARP investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2015.08.007_bib19","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2015.08.007_bib20","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/pst.1680","article-title":"Assessing the treatment effect estimate in a randomized controlled trial with extensive non-adherence: the EVOLVE trial","volume":"14","author":"Kubo","year":"2015","journal-title":"Pharm Stat"},{"key":"10.1016\/j.jval.2015.08.007_bib21","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"key":"10.1016\/j.jval.2015.08.007_bib22","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2165\/11584620-000000000-00000","article-title":"Cost estimation of cardiovascular disease events in the US","volume":"29","author":"O\u2019Sullivan","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2015.08.007_bib23","unstructured":"Bureau of Labor Statistics, US Department of Labor. Consumer Price Index\u2014All Urban Consumers (Current Series). Bureau of Labor Statistics, US Department of Labor. 2013. Available from: www.bls.gov [Accessed July 25, 2013]."},{"key":"10.1016\/j.jval.2015.08.007_bib24","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/ki.2010.167","article-title":"Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients","volume":"78","author":"Block","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.jval.2015.08.007_bib25","unstructured":"United States Renal Data System, Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2013."},{"key":"10.1016\/j.jval.2015.08.007_bib26","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(08)61239-8","article-title":"Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized double-blind placebo-controlled clinical trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2015.08.007_bib27","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1001\/jama.2009.454","article-title":"Efficacy and safety of exercise training in patients with chronic heart failure: HFACTION randomized controlled trial","volume":"301","author":"O\u2019Connor","year":"2009","journal-title":"Jama"},{"key":"10.1016\/j.jval.2015.08.007_bib28","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2015.08.007_bib29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/hec.584","article-title":"The death of cost-minimization analysis?","volume":"10","author":"Briggs","year":"2001","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2015.08.007_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3111\/13696998.2012.718019","article-title":"A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom","volume":"16","author":"Bernard","year":"2013","journal-title":"J Med Econ"},{"key":"10.1016\/j.jval.2015.08.007_bib31","doi-asserted-by":"crossref","first-page":"798","DOI":"10.3111\/13696998.2011.627404","article-title":"Association of cinacalcet adherence and costs in patients on dialysis","volume":"14","author":"Lee","year":"2011","journal-title":"J Med Econ"},{"key":"10.1016\/j.jval.2015.08.007_bib32","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1053\/j.ajkd.2007.03.009","article-title":"Parathyroidectomy versus cinacalcet hydrochloride\u2013based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis","volume":"49","author":"Narayan","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jval.2015.08.007_bib33","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1210\/jc.2013-2975","article-title":"The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial","volume":"98","author":"Parfrey","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jval.2015.08.007_bib34","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1542-4758.2011.00642.x","article-title":"Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols","volume":"16","author":"Chertow","year":"2011","journal-title":"Hemodial Int"},{"key":"10.1016\/j.jval.2015.08.007_bib35","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jama.1996.03540140060028","article-title":"Role of cost-effectiveness analysis in health and medicine: consensus statement","volume":"276","author":"Russell","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.jval.2015.08.007_bib36","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.2215\/CJN.03530410","article-title":"Clinical practices and outcomes in elderly hemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"6","author":"Canaud","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jval.2015.08.007_bib37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1524-4733.2009.00660.x","article-title":"Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report\u2014part II","volume":"13","author":"Garrison","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2015.08.007_bib38","unstructured":"Grima DT, Mendelssohn DC, Mcfarlane P, et al. Inclusion of dialysis costs in cost-effectiveness analyses of therapies for patients in dialysis: a case study of sevelamer for the treatment of hyperphosphatemia. In: HTA For Health Systems Sustainability, 8th annual meeting. Rio De Janeiro, June 27-29, 2011."},{"key":"10.1016\/j.jval.2015.08.007_bib39","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2015.08.007_bib40","unstructured":"Lee A, Song X, Belozeroff V, et al. Costs of care and major clinical events among chronic dialysis patients with and without treatment for sHPT: a descriptive study of claims data. Poster presented at: the American Society of Nephrology Annual Conference. Philadelphia, PA, November 8-13, 2011."},{"key":"10.1016\/j.jval.2015.08.007_bib41","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/1472-6963-13-248","article-title":"Healthcare use and costs before and after parathyroidectomy in patients on dialysis","volume":"13","author":"Belozeroff","year":"2013","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.jval.2015.08.007_bib42","unstructured":"Red Book. 2013. Available from: www.micromedexsolutions.com. [Accessed July 25, 2013]."},{"key":"10.1016\/j.jval.2015.08.007_bib43","first-page":"5","article-title":"Analysing Health-related Quality of Life in the EVOLVE trial: the joint impact of treatment and clinical events. Poster presented at: the American Society of Nephrology Annual Conference","author":"Briggs","year":"2013","journal-title":"Atlanta, GA, November"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301515020355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301515020355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T10:58:35Z","timestamp":1537268315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301515020355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1098301515020355"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2015.08.007","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2015.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}